Atypical antipsychotic and compliance in schizophrenia

References

• Kane J M. Compliance issues in outpatient treatment. J Clin Psychopharmacol 1985; 5: 225–75
   Google Scholar
• Kissling W, Fleischhacker W W, Helmcher H, et al. Optimising prophylactic treatment of schizophrenia by means of treatment standards and compliance improvement. Pharmacopsychiatry 1992; 25: 69–71
   Google Scholar
• American Psychiatric Association. American Psychiatric: Task Force on Treatment of Psychiatric Disorders. APA, Washington, DC 1989; Vol 2: 1507–09
   Google Scholar
• Kissling W. Guidelines for neuroleptic relapse prevention in schizophrenia. Springer-Ver-lag, Berlin 1991
   Google Scholar
• Shepherd D, Watt D, Falloon I, Smeeton N. The natural history of schizophrenia: a five year follow-up study of outcome and prediction in a representative sample of schizophrenia. Psychol Med 1989; 22(suppl 15)
   Google Scholar
• Johnstone E C, Frith C D, Crow T J, et al. The Northwick Park functional psychosis study: diagnosis and outcome. Psychol Med 1992; 22: 331–46
   PubMedGoogle Scholar
• Davis J M, Ware J M, Master S R, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry 1993; 54(suppl)24–30
   PubMed Web of Science ®Google Scholar
• Lam D. Psychosocial family intervention in schizophrenia: a review of empirical studies. Psychol Med 1991; 21: 423–41
   PubMed Web of Science ®Google Scholar
• Mann J J. How medication compliance affects outcome. Psychiatric Annals 1986; 42: 866–71
   Google Scholar
• Kane J M. Problems of compliance in the outpatient treatment of Schizophrenia. J Clin Psychiatry 1983; 44(6)3–6, II
   Google Scholar
• McEvoy J P, Apperson L J, Applebaum P S, Ortlip P, et al. Insight in schizophrenia: its relationship to acute psychopathology. J Nerv Ment Dis 1989; 177: 43–7
   PubMed Web of Science ®Google Scholar
• Haynes R B, Tayler D U, Sackett D L. Compliance in health care. Johns Hopkins University Press, Baltimore
   Google Scholar
• Sleator E K. Measurement of compliance. Psychopharmacol Bull 1985; 21: 1089–93
   Google Scholar
• McCreadie R G, Wiles D H, Moore J W, Grant S M, et al. The Scottish first episode schizophrenia study: II. Treatment: Pimozide versus flupenthixol. Br J Psychiatry 1987; 150: 334–8
   Google Scholar
• Goad J D, Ezell J R. Drug-use evaluation programs for psychotropic medications. Am J Hosp Pharm 1990; 47: 132–6
   Google Scholar
• Van Putten T, Marder S R, Wirshing W C, Chabert N, et al. Surreptitious noncompliance with oral fluphenazine in a voluntary inpatient population. Arch Gen Psychiatry 1990; 47: 786–7, (original text)
   Google Scholar
• Young J L, Zonana H V, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law. 1986; 14(2)105–22
   PubMedGoogle Scholar
• Krska J, Sampath G, Shah A, Soni S D. Radio receptor assay of serum neuroleptic levels in psychiatric patients. Br J Psychiatry 1986; 148: 187–93
   Google Scholar
• Van Putten T, Marder S R, Wirshing W C, Aravagiri M, Chabert N. Neuroleptic plasma levels. Schiz Bull 1991; 17: 197–216
   PubMed Web of Science ®Google Scholar
• Carman J S, Wyatt E S, Fleck R, Martin D, et al. Neuroleptic compliance in schizophrenic outpatients. Psychiatr Hosp 1984; 15: 173–8
   Google Scholar
• Kapur S, Ganguli R, Ulrich R, Raghu U. Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. Schiz Res. 1991; 6(l)49–53
   Google Scholar
• Johnson D AW, Wright N. Drug prescribing to schizophrenic outpatients on depot injections: repeat surveys over 18 years. Br J Psychiatry 1990; 156: 827–34
   PubMed Web of Science ®Google Scholar
• Simpson G M. A brief history of depot neuroleptics. J Clin Psychiatry 1984; 45(5/11)3–1
   Google Scholar
• Tegeler J, Lehmann E, Stockschlaeder M. Prophylactic efficacy of long-acting vs short-acting neuroleptics in schizophrenic out-patients. Nervenarzt 1980; 511: 654–61
   Google Scholar
• Gottfries C G, Green L. Fluophentixol decanoate in treatment of outpatients. Acta Psych Scand 1974; 15–23, (Supp. 225)
   Google Scholar
• Johnson D AW. Depot therapy - advantages, disadvantages and issues of dose. Depot antipsychotics in chronic schizophrenia, E B Wistedt, J Gerach. Excerpta Medica, Amsterdam 1991; 4: 16
   Google Scholar
• Hogarty G E, Schroder N R, Ulrich R, et al. Fluphenazine and social therapy in the after care of schizophrenic patients. Relapse analysis of a 2 year controlled study of fluphenazine decanoate and fluophenazine hydrochloride. Arch Gen Psychiatry 1979; 36: 1283–94
   PubMed Web of Science ®Google Scholar
• Davis J M, Andriukaitis S. The normal course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacology 1986; 6: 25–105
   Google Scholar
• Glazer W M, Kane J M. Depot neuroleptic therapy: an under utilized treatment option. J Clin Psychiatry 1992; 53: 426–33
   PubMed Web of Science ®Google Scholar
• Kane J M. Prevention and treatment of neuroleptic noncompliance. Psychiatric Annals 1986; 16: 576–79
   Web of Science ®Google Scholar
• Frånces A J, Weiden P. Promoting compliance with outpatient drug treatment. Hosp Commun Psychiatry 1987; 38: 1158–60
   Google Scholar
• Willcox D RC, Gillan R, Hare E V. Do psychiatric outpatients take their drug?. BMJ 1965; 2: 790–922
   PubMed Web of Science ®Google Scholar
• Perenyi A, Goswami U, Frecska E, Majlath E, et al. A pilot study of the role of prophylactic antipar-kinson treatment during neuroleptic therapy. Pharmacopsychiatry 1989; 22(3)108–10
   Google Scholar
• Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992; 22: 787–97
   PubMed Web of Science ®Google Scholar
• David A S. Insight and psychosis. Br J Psychiatry 1990; 156: 798–808
   PubMed Web of Science ®Google Scholar
• Axelrod S, Palgi E. Developing an alliance with schizophrenic patients in day hospital treatment. Bull Meninger Clin 1990; 54: 340–52
   PubMedGoogle Scholar
• Corrigan P W, Liberman R P, Engel J D. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Commun. Psychiatry 1990; 41: 1203–11
   Google Scholar
• Geisen L, Feuer E. The treatment resistant patient and the need to stay crazy. Psychiatric Q 1984; 56: 75–82
   Google Scholar
• Bossert-Zaudig S, Dose M, Emrich H M, Garcia D, et al. Psychological effects of previous experience with neuroleptics. Nervenarzt 1990; 61: 301–6
   Google Scholar
• Van Putten T, May P RA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 477–80
   PubMed Web of Science ®Google Scholar
• Marder S R, Van Putten T, Mintz J, et al. Cost and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984; 41: 1025–9
   PubMed Web of Science ®Google Scholar
• Halstead S M, Barros T RE, Speller J C. Akathisia: prescribed and associated dysphoria in a hospital population with chronic schizophrenia. Neuropsy-chopharmacology 1994; 164: 177–83
   Google Scholar
• Van Putten T, May P RA, Marder S R. Response to antipsychotic medication: the doctor's and the consumer's view. Am J Psychiatry 1984; 141: 16–19
   PubMed Web of Science ®Google Scholar
• Gift T E, Gift J M. Depot fluphenazine and depression: possible mechanism. J Psychiatry Treat Eval 1981; 3(6)557–8
   Google Scholar
• Pan P C, Tantam D. Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic. Acta Psych Scand 1989; 79: 564–70
   PubMed Web of Science ®Google Scholar
• McEvoy J P, Howe A C, Hogarty G E. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and non-compliant schizophrenic patients. J Nerv Ment Dis 1984; 172: 412–16
   Web of Science ®Google Scholar
• Bartko G, Maylath E, Herczeg I. Comparative study of schizophrenic patients relapsed on and off medication. Psychiatry Res 1987; 22: 221–7
   Google Scholar
• Bartko G, Herczeg I, Zador G. Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatr Scand 1988; 77: 74–6
   PubMed Web of Science ®Google Scholar
• Zito J M, Sofair J B, Jaeger J. Self-reported neuroendocrine effects of antipsychotics in women: a pilot study. Drug Int Clin Pharm Annals Pharmacother 1990; 24: 176–80
   Google Scholar
• Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988; 153: 214–17
   PubMed Web of Science ®Google Scholar
• Pfeiffer W, Kockott G, Fischer B, Schluning G. Unerwtinschte Wirkungen psychopharmacologis-cher Langzeitherapie auf die sexuelle Funktionen. Psychiatr Prax 1991; 18: 998
   Google Scholar
• Drake R E, Wallach M A, Teague G B, Freeman D H, Paskus T S, Clark T A. Housing instability and homelessness among rural schizophrenic patients. Am J Psychiatry 1991; 148: 330–6
   PubMed Web of Science ®Google Scholar
• Pristach C A, Smith C M. Medication compliance and substance abuse among schizophrenic patients. Hosp Com Psychiatry 1990; 41: 43–7
   Google Scholar
• Blondiaux I, Alagille M, Ginestet D. Neuroleptic treatment adherence in schizophrenic patients. En-cephale 1988; 14(6)301–6
   Google Scholar
• Seltzer A, Roncari I, Garfmkel P. Effect on patient education on medication compliance. Can J Psychiatry 1980; 25(8)638–45
   Google Scholar
• Munetz M R, Roth L H. Informing patients about tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 866–71
   Google Scholar
• Brown C S, Wright R G, Christensen D B. Association between type of medication instruction and patients' knowledge, side effects, and compliance. Hosp Com Psychiatry 1987; 38(l)55–60
   Google Scholar
• Kleinman I, Schachter D, Koritar E. Informed consent and tardive dyskinesia. Am J Psychiatry 1989; 146(7)902–4
   Google Scholar
• Geller J L. State hospital patients and their medication - do they know what they take?. Am J Psych 1982; 139: 611–15
   Google Scholar
• MacDonald E T, Macdonald J B, Phoenix M. Improving drug compliance after hospital discharge. BMJ 1977; 2: 618–21
   PubMed Web of Science ®Google Scholar
• Diamond R J. Enhancing medication use in schizophrenic patients. J Clin Psychiatry 1983; 64: 7–14
   Google Scholar
• Smith J, Birchwood M J, Hadrell A. Informing people with schizophrenia about their illness of residual symptoms. J Mental Health 1992; 1: 61–70
   Google Scholar
• Hogarty G E, Anderson C M, Reiss D J, Kornblith S J, Greenwald D P, Ulrich R F, Carter M. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. II. Two-year effects of a controlled study on relapse and adjustment. Environmental-Personal Indicators in the Course of Schizophrenia (EPICS) Research Group. Arch Gen Psychiatry 1991; 48(4)340–7
   PubMedGoogle Scholar
• Smith J, Birchwood M J. Specific and non-specific effects of educational intervention with families living with a schizophrenic relative. Br J Psychiatry 1987; 150: 645–52
   PubMed Web of Science ®Google Scholar
• Bäuml J, Kissling W, Butter P, et al. Information zertiere Patienten und Angehorigengruppen Zur Complianceverbesserung bei schizophren Psy-chosen. Psychoser. Verhaltenstherapie 1993; 3(Suppl l)1–96
   Google Scholar
• Summerfelt A T, Alphs L D, Funderburk F R, Strauss M E, Wagman A M. Impaired Wisconsin Card Sort performance in schizophrenia may reflect motivational deficits. Arch Gen Psychiatry 1991; 48(3)282–3
   Google Scholar
• Cutmore T R, Beninger R J. Do neuroleptics impair learning in schizophrenic patients?. Schizophrenia Res 1990; 3(3)173–86
   Google Scholar
• Bird M, Kornetsky C. Dissociation of the attentional and motivational effects of primozide on the threshold for rewarding brain stimulation. Neuropsychopharmacology 1990; 3(1)33–40
   Google Scholar
• Rollnick S, Heather N, Bell A. Negotiating behaviour change in medical settings: the development of brief motivational interviewing. J Men Health 1992; 1: 25–37
   Google Scholar
• Melzer D, Hale A S, Malik S J, Hogman G A, Wood S. Community care for patients with schizophrenia one year after hospital discharge. BMJ 1991; 303: 1023–6
   PubMed Web of Science ®Google Scholar
• Cassino T, Spellman N, Heiman J, Shupe J, et al. Invitation to compliance: the Prolixin brunch. J Psychosoc Nurs Mental Health Services 1987; 25: 15–19
   Google Scholar
• Kane J M, Honigfeld G, Singer J, Meltzer M. Clozapine for treatment resistant schizophrenia. Arch Gen Psychiatry 1988; 45: 789–96
   PubMed Web of Science ®Google Scholar
• Fitton A, Heel R C. Clozapine. A review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990; 40(5)722–47
   PubMed Web of Science ®Google Scholar
• Paunovic V R, Jasovix-Casic M H, Bogdanovic M R, Totic S D. Clozapine in the treatment of negative symptoms of schizophrenia. Psychopharmacology 1988; 36(suppl)344
   Google Scholar
• Sanches C, Ann J, Dragsted N, Hyttel J, Lembol H L, Meier E, Perregard J, Skarsfeldt T. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 1991; 22: 239–50
   Google Scholar
• Van Tol H HM, Bunzow J R, Guar H C, Sunahara R K, Seaman P, et al. Cloning the gene for a human depressive receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610–14
   PubMed Web of Science ®Google Scholar
• Canton H, Verriele L, Colpert F C. Binding of typical and atypical antipsychotics to 5-HT-1C and 5-HT-2 sites; clozapine potently interacts with 5-HT-1C sites. Eur J Clin Pharmacol 1990; 191: 93–6
   Google Scholar
• Hogarty G E. Depot neuroleptics. The relevance of psychosocial factors. J Clin Psychiatry 1984; 45: 36–42
   PubMed Web of Science ®Google Scholar
• Cognos Study 7 Schizophrenia. Decision Resources Inc, Burlington, Massachusetts 1992
   Google Scholar
• Song F, Freemantle N, Sheldon T A, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683–7
   PubMed Web of Science ®Google Scholar
• Lindstrom L H. A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychopharmacology 1989; 99(Suppl)S84–S86
   Google Scholar